Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

FLUTICASONE PROPIONATE

All products: not a benefit

Other products in the same Health Canada class (R01AD) — coverage varies; not interchangeable

  • Beclomethasone dipropionate (Mylan-Beclo AQ): general benefit, Not a benefit
  • Budesonide (Rhinocort Aqua): general benefit, Not a benefit
  • Azelastine + fluticasone (Dymista): not a benefit
  • Mometasone furoate (Nasonex): not a benefit
  • Triamcinolone acetonide (Nasacort AQ): not a benefit

Flonase · DIN 02213672 · 50mcg/Actuation · Nas Sp-120 Dose Pk

Off-Formulary Interchangeable, not an ODB benefit; Health Canada lists this DIN as Cancelled post market since 2017-04-07 — choose a marketed DIN from the same-category list.Discontinued 2017-04-07 · checked 2026-09-19
StatusOff-Formulary Interchangeable, not an ODB benefit; Health Canada lists this DIN as Cancelled post market since 2017-04-07 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives; Health Canada lists this DIN as Cancelled post market since 2017-04-07 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Flonase · DIN 02213672 Manufacturer: GlaxoSmithKline Inc., GlaxoSmithKline Consumer Health Care; listing date 2007-11-10 Health Canada: Cancelled post market since 2017-04-07 · brand FLONASE - AEM-SUS NAS 50MCG/MD · ATC R01AD08 FLUTICASONE · form Metered-dose pump · route Nasal · ingredients FLUTICASONE PROPIONATE 50 MCG/ACT · company Glaxosmithkline inc · schedule Prescription
Check this DIN again · Health Canada product record

Flonase: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=43126 · Verify on the e-Formulary ↗ (DIN 02213672)

Source record
DIN 02213672: Flonase Raw flags: notABenefit=Y, sec3=Y, sec3b=Y Item: 520800035; group id 596; item number 1555; lccId None; manufacturer id GSK Source form: Nas Sp-120 Dose Pk; strength: 50mcg/Actuation Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02213672 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=43126
Interchangeable products
Apo-Fluticasone · DIN 02294745 · not recorded Ratio-Fluticasone · DIN 02296071 · not recorded Teva-Fluticasone · DIN 02453738 · not recorded
Shortage status: not checked (no credentials)
Health Canada lists this DIN as Cancelled post market since 2017-04-07 — choose a marketed DIN from the same-category list.
Other drugs in the same formulary class (52:08 Anti-Inflammatory Agents) and how they are covered

Matched class: 52:08 Anti-Inflammatory Agents

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: DEXAMETHASONE, FLUMETHASONE PIVALATE & IODOCHLORHYDROXYQUIN, FLUOROMETHOLONE, FLUOROMETHOLONE ACETATE, KETOROLAC TROMETHAMINE, LODOXAMIDE TROMETHAMINE Some products covered without a code (check the product listing): BECLOMETHASONE DIPROPIONATE, BUDESONIDE, PREDNISOLONE ACETATE 52:08 Anti-Inflammatory Agents

BECLOMETHASONE DIPROPIONATE

· 3 products · General benefit (2), Listed, not a benefit (1) · strengths: 50mcg · Nas-Sp-200 Dose Pk

BUDESONIDE

· 3 products · General benefit (2), Listed, not a benefit (1) · strengths: 64mcg/Metered Dose, 100mcg/Metered Dose · Nas Sp-120 Dose Pk, Nas Sp-165 Dose Pk

AZELASTINE HCL & FLUTICASONE PROPIONATE

· 3 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 137mcg/Actuation&50mcg/Actuation · Nas-Sp-120 Dose Pk

MOMETASONE FUROATE

· 6 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 50mcg/Dose · Nas Sp-140 Dose Pk

TRIAMCINOLONE ACETONIDE

· 2 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 55mcg/Metered Dose · Nas Sp-120 Dose Pk (with Preservative)

DEXAMETHASONE

· 2 products · General benefit · strengths: 0.1% · Oph Oint-3.5g Pk, Oph Susp

FLUMETHASONE PIVALATE & IODOCHLORHYDROXYQUIN

· 1 products · General benefit · strengths: 0.02% & 1% · Ot Sol

FLUOROMETHOLONE

· 1 products · General benefit · strengths: 0.1% · Oph Susp

FLUOROMETHOLONE ACETATE

· 1 products · General benefit · strengths: 0.1% · Oph Susp

KETOROLAC TROMETHAMINE

· 3 products · General benefit · strengths: 0.5%, 0.45% w/v · Oph Sol, Oph Sol-0.4mL Vial Pk (Preservative-Free)

LODOXAMIDE TROMETHAMINE

· 1 products · General benefit · strengths: 0.1% · Oph Sol

PREDNISOLONE ACETATE

· 2 products · Listed, not a benefit (1), General benefit (1) · strengths: 1% · Oph Susp Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 52:08 and 2 more
Full class listing Related classes: 52:04 Anti-Infectives, 52:16 Local Anesthetics, 52:20 Miotics, 52:24 Mydriatics, 52:32 Vasoconstrictors, 52:36 Other Eye, Ear, Nose and Throat Agents Same formulary class, not same indication: class membership alone does not establish equivalent uses.
Other drugs whose Health Canada label lists a similar indication: steroid-responsive bronchial asthma
From Health Canada product monographs; label wording only, not a treatment recommendation. Matching is lexical and uses one held product label per generic; formulations and qualifying criteria may differ. Covered without a code on the Ontario formulary: CICLESONIDE, FLUTICASONE FUROATE CICLESONIDE · General benefit INDICATIONS AND CLINICAL USE ALVESCO (ciclesonide) is indicated for:  prophylactic management of steroid-responsive bronchial asthma in adults, adolescents and children 6 years of age and older. PM: https://pdf.hres.ca/dpd_pm/00060608.PDF; date March 30, 2021; DIN 02285606; fetched 2026-09-10 Product monograph FLUTICASONE FUROATE · General benefit 1 INDICATIONS ARNUITY ELLIPTA (fluticasone furoate) is indicated for the once-daily maintenance treatment of steroid-responsive bronchial asthma in patients aged 12 years and older. PM: https://pdf.hres.ca/dpd_pm/00072514.PDF; date September 21, 2015; DIN 02446561; fetched 2026-09-10 Product monograph Coverage source: ON formulary extract 2026-08-26
What the Health Canada label says it is for
1 INDICATIONS FLOVENT (fluticasone propionate) is indicated for:  the prophylactic management of steroid-responsive bronchial asthma in adults and children (12 months of age or older). For children, this includes patients not controlled on currently available prophylactic medication. FLOVENT is not indicated for the relief of acute bronchospasm (see 7 WARNINGS AND PRECAUTIONS, general). 1.1 Pediatrics Pediatrics (12 months of age and older): FLOVENT DISKUS is indicated for any child 4 years of age and older, and FLOVENT HFA inhalation aerosol is indicated for children 12 months of age and above who require prophylactic medication, including patients not controlled on currently available prophylactic medication. At present there are insufficient clinical data to recommend the use of FLOVENT DISKUS in children younger than 4 years and the use of FLOVENT HFA inhalation aerosol in children younger than 12 months. 1.2 Geriatrics There is no need to adjust the dose in elderly patients. https://pdf.hres.ca/dpd_pm/00060119.PDF PM date: March 1, 2021 Source product: FLOVENT DISKUS; DIN 02237246; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.

Other review policies

For Flonase: no applicable EAP criteria are held and no ODB benefit is established. These policies do not establish coverage.

For rare, immediately life-, limb- or organ-threatening circumstances, the Compassionate Review Policy may consider an unfunded drug or indication, subject to its criteria and without bypassing the drug review process. Compassionate Review Policy

Compassionate Review Policy: source quote
Where there are rare clinical circumstances in immediately life, limb, or organ-threatening conditions, the Executive Officer will also consider requests for drugs or indications in situations where there has not been a decision by the Executive Officer to provide funding of the drug or indication as part of the Ontario Drug Benefit program (and the EAP), and the drug or indication requested would not circumvent the established review process for new drugs or indications as part of the drug submission process for listing within the Ontario Drug Benefit program. Requests must meet the criteria for the Compassionate Review Policy.

Ontario source; updated September 15, 2026

For cancer drugs, Case-by-Case Review considers rare, immediately life-threatening circumstances when no satisfactory funded treatment exists; its criteria and application process apply. Case-by-Case Review (cancer drugs)

Case-by-Case Review (cancer drugs): source quote
Note: Requests for cancer drugs are considered under the Case-by-Case Review Program (CBCRP) which is administered by Ontario Health (Cancer Care Ontario) on behalf of the Ministry of Health. The CBCRP considers funding requests for drugs (both oral therapies and injectable drugs) for the treatment of cancer in patients who have a rare clinical circumstance that is immediately life-threatening (death is likely within a matter of months) and who require treatment with an unfunded drug, because there is no other satisfactory and funded treatment. Please refer to the Ontario Health website for information on the application process, FAQs, eligibility criteria and program policies.

Ontario source; updated September 15, 2026